Developer docs
API playgroundTry for free, no card

Search company profiles

Provectus Pharmaceuticals

Full company profile

uuid0038v56

Namestring
Provectus Pharmaceuticals
Legal namestring
Provectus Biopharmaceuticals, Inc.
Websiteurl
http://pvct.com
Company typeenum
Public
Founded yearint
1978
Descriptiontext

Provectus Pharmaceuticals (legal name: Provectus Biopharmaceuticals, Inc.) is a clinical-stage biopharmaceutical company headquartered in Knoxville, Tennessee, that develops advanced therapies aimed at destroying cancers such as melanoma, liver, and breast cancer. The company is publicly traded on the OTCQB market under the ticker PVCT and was founded in 1978. According to publicly available data, the company employs 51-100 people and is led by Chairman and CEO Ed Pershing, with legacy executives Craig Dees, Eric Wachter (CTO), and Timothy Scott (President) associated with its drug development platform. Its operating focus is on the research and clinical development of oncology therapeutics rather than on commercialized product sales.

Short descriptiontext

Provectus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops advanced oncology therapies targeting cancers such as melanoma, liver, and breast cancer, with no commercialized products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKnoxville, United States
HQ citystring
Knoxville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceuticals, oncology drug development, cancer therapeutics research, novel pharmaceutical discovery, investigational cancer drugs
Industry1 code
1Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
CodeHLAAAAABPrimaryYes
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-Stage Oncology Biopharmaceuticals
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Provectus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops advanced investigational therapies intended to destroy cancers such as melanoma, liver cancer, and breast cancer. The company has no commercialized products and is dependent on grant revenue and capital raises to fund ongoing research and development activities.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Provectus Pharmaceuticals (also known as Provectus Biopharmaceuticals, Inc.) is a biopharmaceutical company focused on clinical development. Based on the available source material, no specific named products, drug candidates, or therapeutic programs have been identified from the provided sources.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Celsion Corporation
TypeDirect peer
Description

Celsion is a small clinical-stage oncology biopharmaceutical company, most notably for liver cancer therapies (ThermoDox), making it structurally and therapeutically comparable to Provectus's oncology focus, particularly liver cancer.

2Soligenix, Inc.
TypeDirect peer
Description

Soligenix is a late-stage clinical biopharmaceutical company developing treatments for rare diseases and oncology indications. It shares the small-cap clinical-stage biotech profile of Provectus with similar capital constraints and pipeline characteristics.

3Onconova Therapeutics, Inc.
TypeDirect peer
Description

Onconova is a clinical-stage oncology biopharmaceutical company with small-molecule drug candidates. It is comparable to Provectus as a similarly small, publicly-listed biotech focused on cancer therapeutics with limited commercial revenue.

4Moleculin Biotech, Inc.
TypeDirect peer
Description

Moleculin is a clinical-stage pharmaceutical company developing oncology drug candidates. Its profile of being a small clinical-stage biotech with multiple cancer programs directly parallels Provectus's clinical development model.

5Aprea Therapeutics, Inc.
TypeDirect peer
Description

Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies that target underlying mechanisms of cancer. Its clinical-stage oncology focus makes it functionally and structurally comparable to Provectus.

6Actinium Pharmaceuticals, Inc.
TypeDirect peer
Description

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer. Its small-cap clinical-stage oncology profile and public listing status make it a strong comparable to Provectus.

7Advaxis, Inc.
TypeDirect peer
Description

Advaxis is a clinical-stage biotechnology company developing immunotherapies for cancer. The clinical-stage oncology focus combined with public listing status makes it a comparable peer to Provectus Pharmaceuticals.

8DelMar Pharmaceuticals, Inc.
TypeDirect peer
Description

DelMar Pharmaceuticals is a clinical-stage drug development company focused on cancer therapeutics. Its small-cap clinical-stage oncology profile and similar structural challenges make it a relevant direct peer to Provectus.

9Tiziana Life Sciences Ltd.
TypeEmerging player
Description

Tiziana Life Sciences is a clinical-stage biotechnology company with oncology and immunology programs. Its small-cap clinical-stage biotech profile makes it comparable in scale and stage to Provectus, though it has a broader therapeutic focus.

10Hemispherx Biopharma, Inc.
TypeDirect peer
Description

Hemispherx Biopharma is a small clinical-stage biopharmaceutical company developing therapies for cancer and immune disorders. Its long-standing clinical-stage status, small market capitalization, and ongoing capital-raising challenges make it a structurally comparable peer to Provectus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Provectus Pharmaceuticals

Clinical-Stage Oncology Biopharmaceuticalspvct.com

Provectus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops advanced oncology therapies targeting cancers such as melanoma, liver, and breast cancer, with no commercialized products.

What Provectus Pharmaceuticals does

Provectus Pharmaceuticals (legal name: Provectus Biopharmaceuticals, Inc.) is a clinical-stage biopharmaceutical company headquartered in Knoxville, Tennessee, that develops advanced therapies aimed at destroying cancers such as melanoma, liver, and breast cancer. The company is publicly traded on the OTCQB market under the ticker PVCT and was founded in 1978. According to publicly available data, the company employs 51-100 people and is led by Chairman and CEO Ed Pershing, with legacy executives Craig Dees, Eric Wachter (CTO), and Timothy Scott (President) associated with its drug development platform. Its operating focus is on the research and clinical development of oncology therapeutics rather than on commercialized product sales.

Provectus Pharmaceuticals firmographics

Firmographics
Name
Provectus Pharmaceuticals
Legal name
Provectus Biopharmaceuticals, Inc.
Website
http://pvct.com
Company type
Public
Founded year
1978
Operating status
Operating
Headcount range
51–100 employees
Short description
Provectus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops advanced oncology therapies targeting cancers such as melanoma, liver, and breast cancer, with no commercialized products.
Ownership category
akta.pro rank

Provectus Pharmaceuticals industry classification

Industry
Product category
Clinical-Stage Oncology Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

Keywords

  • Clinical-stage biopharmaceuticals
  • Oncology drug development
  • Cancer therapeutics research
  • Novel pharmaceutical discovery
  • Investigational cancer drugs

Where Provectus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Knoxville
HQ country
United States
HQ region
North America

Markets served

Provectus Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Provectus Pharmaceuticals product offering

Product offering

Core offering

Provectus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops advanced investigational therapies intended to destroy cancers such as melanoma, liver cancer, and breast cancer. The company has no commercialized products and is dependent on grant revenue and capital raises to fund ongoing research and development activities.

Product overview

Provectus Pharmaceuticals (also known as Provectus Biopharmaceuticals, Inc.) is a biopharmaceutical company focused on clinical development. Based on the available source material, no specific named products, drug candidates, or therapeutic programs have been identified from the provided sources.

Differentiator

Problem solved

Functional benefit

Companies that use Provectus Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Provectus Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Provectus Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights2 records

Provectus Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Celsion Corporation: Celsion is a small clinical-stage oncology biopharmaceutical company, most notably for liver cancer therapies (ThermoDox), making it structurally and therapeutically comparable to Provectus's oncology focus, particularly liver cancer.
  • Soligenix, Inc. Soligenix is a late-stage clinical biopharmaceutical company developing treatments for rare diseases and oncology indications. It shares the small-cap clinical-stage biotech profile of Provectus with similar capital constraints and pipeline characteristics.
  • Onconova Therapeutics, Inc. Onconova is a clinical-stage oncology biopharmaceutical company with small-molecule drug candidates. It is comparable to Provectus as a similarly small, publicly-listed biotech focused on cancer therapeutics with limited commercial revenue.
  • Moleculin Biotech, Inc. Moleculin is a clinical-stage pharmaceutical company developing oncology drug candidates. Its profile of being a small clinical-stage biotech with multiple cancer programs directly parallels Provectus's clinical development model.
  • Aprea Therapeutics, Inc. Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies that target underlying mechanisms of cancer. Its clinical-stage oncology focus makes it functionally and structurally comparable to Provectus.
  • Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer. Its small-cap clinical-stage oncology profile and public listing status make it a strong comparable to Provectus.
  • Advaxis, Inc. Advaxis is a clinical-stage biotechnology company developing immunotherapies for cancer. The clinical-stage oncology focus combined with public listing status makes it a comparable peer to Provectus Pharmaceuticals.
  • DelMar Pharmaceuticals, Inc. DelMar Pharmaceuticals is a clinical-stage drug development company focused on cancer therapeutics. Its small-cap clinical-stage oncology profile and similar structural challenges make it a relevant direct peer to Provectus.
  • Hemispherx Biopharma, Inc. Hemispherx Biopharma is a small clinical-stage biopharmaceutical company developing therapies for cancer and immune disorders. Its long-standing clinical-stage status, small market capitalization, and ongoing capital-raising challenges make it a structurally comparable peer to Provectus.

Emerging players

  • Tiziana Life Sciences Ltd. Tiziana Life Sciences is a clinical-stage biotechnology company with oncology and immunology programs. Its small-cap clinical-stage biotech profile makes it comparable in scale and stage to Provectus, though it has a broader therapeutic focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights4 records

Customer concentration

Provectus Pharmaceuticals social profiles

Digital presence

Provectus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Provectus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles4 records

Provectus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Provectus Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Provectus Pharmaceuticals

What does Provectus Pharmaceuticals do?

Provectus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops advanced investigational therapies intended to destroy cancers such as melanoma, liver cancer, and breast cancer. The company has no commercialized products and is dependent on grant revenue and capital raises to fund ongoing research and development activities.

Is Provectus Pharmaceuticals a public or private company?

Provectus Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Provectus Pharmaceuticals founded?

Provectus Pharmaceuticals was founded in 1978. It employs 51 to 100 people.

Where is Provectus Pharmaceuticals based?

Provectus Pharmaceuticals is headquartered in Knoxville, United States, in the North America region.

Who are Provectus Pharmaceuticals's main competitors?

Direct peers on record are Celsion Corporation, Soligenix, Inc., Onconova Therapeutics, Inc., Moleculin Biotech, Inc., Aprea Therapeutics, Inc., Actinium Pharmaceuticals, Inc., Advaxis, Inc., DelMar Pharmaceuticals, Inc. and Hemispherx Biopharma, Inc.. Tiziana Life Sciences Ltd. is listed as an emerging player.

Does Provectus Pharmaceuticals have an API?

No public API is recorded for Provectus Pharmaceuticals.

What industry is Provectus Pharmaceuticals in?

Provectus Pharmaceuticals's product category is Clinical-Stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewProvectus converts directors' accrued fees into Series D-1 Preferred StockProvectus converted accrued but unpaid directors' fees through June 30, 2026 into Series D-1 Preferred Stock, issuing 189,554 shares to current board members. The accrued fees totaled $542,500, convertible into 1,895,540 common shares.Seeking AlphaProvectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call TranscriptThis is the opening segment of Provectus Biopharmaceuticals' 2026 Annual Stockholder Meeting call, facilitated by Susan Xu from Alliance Advisors. The transcript contains standard procedural remarks, technical instructions for participants, and a forward-looking statements disclaimer before turning the meeting over to Ed Pershing, Chairman and CEO. No substantive business content, announcements, or decisions are included in this opening portion of the call.GlobeNewswireProvectus Appoints Heather Raines, CPA as Chief Financial OfficerProvectus appointed Heather Raines as Chief Financial Officer, replacing the interim CFO. She previously served as Controller since 2017 and held finance roles at AMETEK and BDry. The company is developing halogenated xanthenes for oncology and dermatology.GlobeNewswireProvectus Pharmaceuticals, Inc. to Appear on MN1.comProvectus Pharmaceuticals CEO Craig Dees will be interviewed live on MN1.com on Dec. 19, 2006, at 10:00AM CDT. The interview will cover the company's development of treatments for metastatic melanoma, breast cancer, and liver cancer, and its upcoming Phase 2 studies for Xantryl for psoriasis.